NCT04711889 - Protective Effect of Ulinastatin Against Negative Inflammatory Response and Organ Dysfunction After Acute Type a Aortic Dissection Surgery (PANDA I) | Biotech Hunter

Enrollment

203

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions

Acute Aortic SyndromeType a Aortic Dissection

Interventions

DRUG

Ulinastatin

Ulinastatin is taken three times a day.

DRUG

Blank control

Trial Locations (2)

The first affiliated hospital of nanjing medical university, Nanjing

Beijing Anzhen Hospital, Beijing